58375-08-9

Basic information

• Product Name: 1-(6-CHLORO-2-HYDROXY-4-PHENYL-QUINOLIN-3-YL)-ETHANONE
• Synonyms: 1-(6-CHLORO-2-HYDROXY-4-PHENYL-QUINOLIN-3-YL)-ETHANONE;3-Acetyl-6-chloro-4-phenyl-1H-quinolin-2-one;3-acetyl-6-chloro-4-phenyl-carbostyril;6-chloro-3-ethanoyl-4-phenyl-1H-quinolin-2-one;BAS 00991397;Maybridge1_000865;MLS000713991;SMR000273472
• CAS NO: 58375-08-9
• Molecular Formula: C17H12ClNO2
• Molecular Weight: 297.74
• Mol File: 58375-08-9.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-(6-CHLORO-2-HYDROXY-4-PHENYL-QUINOLIN-3-YL)-ETHANONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(6-CHLORO-2-HYDROXY-4-PHENYL-QUINOLIN-3-YL)-ETHANONE(58375-08-9)
• EPA Substance Registry System: 1-(6-CHLORO-2-HYDROXY-4-PHENYL-QUINOLIN-3-YL)-ETHANONE(58375-08-9)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 58375-08-9(Hazardous Substances Data)

Usage

Chemical Properties

White solid

Upstream product

• 141-97-9 ethyl acetoacetate 
• 719-59-5 5-chloro-2-aminobenzophenone 

Downstream Products

• 2205871-61-8 6-chloro-3-[3-(5-fluoropyridin-3-yl)acryloyl]-4-phenyl-1H-quinolin-2-one 

Relevant articles and documents

COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS

The present invention relates to compounds of Formula (Ia) or pharmaceutically acceptable salts, hydrates, solvates, clathrates, polymorphs, stereoisomers thereof. It further discloses a pharmaceutical composition comprising compounds of Formula (Ia) and the use of compounds of Formula (Ib), in particular for the use in the treatment of diseases or disorders wherein disrupting Rad51-BRCA2 interaction is beneficial.

Quinolinones as Inhibitors of Translation Initiation Complex

Provided herein are compounds and pharmaceutical compositions comprising quinolinones. The quinolinones and compositions thereof are useful as eukaryotic translation initiation factor 4F (eIF4F) complex modulators.

Structure-activity relationships and pharmacophore model of a noncompetitive pyrazoline containing class of GluN2C/GluN2D selective antagonists

Here we describe the synthesis and structure-activity relationship for a class of pyrazoline-containing dihydroquinolone negative allosteric modulators of the NMDA receptor that show strong subunit selectivity for GluN2C- and GluN2D-containing receptors over GluN2A- and GluN2B-containing receptors. Several members of this class inhibit NMDA receptor responses in the nanomolar range and are more than 50-fold selective over GluN1/GluN2A and GluN1/GluN2B NMDA receptors, as well as AMPA, kainate, GABA, glycine, nicotinic, serotonin, and purinergic receptors. Analysis of the purified enantiomers of one of the more potent and selective compounds shows that the S-enantiomer is both more potent and more selective than the R-enantiomer. The S-enantiomer had an IC 50 of 0.17-0.22 μM at GluN2D- and GluN2C-containing receptors, respectively, and showed over 70-fold selectivity over other NMDA receptor subunits. The subunit selectivity of this class of compounds should be useful in defining the role of GluN2C- and GluN2D-containing receptors in specific brain circuits in both physiological and pathophysiological conditions.